The step will benefit more fully vaccinated Indians planning travel to the UK without the need for a pre-departure PCR test or self-isolation at the address declared on their compulsory Passenger Locator Forms.
Additionally, starting Jan 15, certain groups of travellers, who are currently exempt from entry requirements, will only be allowed to enter Canada if they are fully vaccinated.
Bharat Biotech was successful in releasing Covaxin in a record time and helped to save lives of crores of fellow Indians, says Director V Krishna Mohan.
The approval comes days after Covaxin received the emergency use listing from WHO.
Recently, WHO granted emergency use listing to Covaxin enabling countries to expedite their regulatory approval to import and administer doses.
Bharat Biotech Chairman and MD Krishna Ella said that the company is looking at nasal vaccine as a booster dose as its scaling up capacity is very easy when compared with Covaxin.
On November 3, the World Health Organisation (WHO) had granted emergency use approval for Covaxin.
The Union Health Minister also informed that under 'Har ghar dastak', healthcare workers are going to all houses to carry out the vaccination drive. 96 countries have recognised Covaxin & Covishield. People can see the list via CoWIN app.
Covishield, the India-manufactured Oxford-AstraZeneca COVID-19 vaccine, was added to the UK's approved list last month.
Bharat Biotech's Covaxin and AstraZeneca and Serum Institute's Covishield are the two widely used vaccines in India.
Today is a big day for 137 crore Indians. The indigenous 'Made in India' vaccine - Covaxin has been approved by WHO. This is the biggest good news before Diwali. Some people are still avoiding the vaccine. However, this is the biggest present ahead of Diwali.
Technical Advisory Group, convened by WHO and made up of regulatory experts from around the world, has determined that Covaxin vaccine meets WHO standards for protection against COVID, that benefit of the vaccine far outweighs risks and the vaccine can be used across the world," the world health body said.
In a tweet, Bharat Biotech said, "The CDSCO has approved the extension of shelf life of Covaxin up to 12 months, from the date of manufacture. This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO."
Meanwhile, Covaxin is yet to receive approval from the World Health Organisation, which last week said it expects to receive clarifications from Bharat Biotech.
Hyderabad-based Bharat Biotech, which has developed Covaxin, had submitted EOI to WHO on April 19 for the vaccine's Emergency Use Listing.
Though Covaxin has been added in the Oman approval list, however, Bharat Biotech is still awaiting its vaccine's approval from the World Health Organization (WHO), which on Tuesday sought additional data to decide on much-awaited Emergency Use Listing (EUL).
Hyderabad-based Bharat Biotech, which has developed Covaxin, had submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine's Emergency Use Listing (EUL).
Earlier this week, the global health organisation had said in a tweet that it is expecting one additional piece of information from Bharat Biotech regarding COVAXIN.
Earlier on Monday, the WHO said it is expecting one additional piece of information from Bharat Biotech regarding its COVID-19 vaccine COVAXIN.
The global health agency also emphasized that it must evaluate a vaccine thoroughly to make sure it is "safe and effective".
Top News
Latest News
